Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ty21a Vivotif combined oral and intratumoral immunotherapy in metastatic cutaneous melanoma
2005-005775-15Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Oct 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of typhoid vaccine, live oral in cutaneous melanoma (CM), sponsored by European Institute of Oncology. Primary endpoints: Grade 3/4 toxicity rate and Objective clinical response. Started Oct 2006; status: completed.
02
Drugs
typhoid vaccine, live oral
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2005-005775-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005775-15.